A groundbreaking new treatment for ovarian cancer is now available on the NHS, bringing fresh hope to hundreds of women across England. The drug, called mirvetuximab soravtansine, not only helps patients live longer but also significantly reduces many of the harsh side effects associated with traditional chemotherapy.
Unlike conventional chemotherapy, which affects healthy and cancerous cells throughout the body, mirvetuximab works in a more targeted way. Often described as a “biological missile” or “Trojan horse” therapy, the drug delivers cancer-fighting medication directly to tumour cells, minimizing damage to healthy tissues and reducing unwanted side effects.
For 64-year-old Patricia Hill from North London, the treatment has been life-changing. Diagnosed with ovarian cancer in 2023, Patricia underwent several rounds of chemotherapy before starting mirvetuximab in January 2026. She describes the difference between the two treatments as “night and day.”
According to Patricia, the new therapy has given her much of her life back. She experiences far less fatigue and nausea than she did with standard chemotherapy, allowing her to enjoy activities that were once impossible. Since beginning treatment, she has attended theatre shows in London’s West End, dined out with friends, visited the Chelsea Flower Show, and travelled to Ireland to spend time with family.
“The treatment opens up so many possibilities,” she said. “You can actually go out and enjoy life again.”
The benefits go beyond improved quality of life. Clinical studies show that patients receiving mirvetuximab lived an average of 16.5 months, compared to 12.8 months for those receiving conventional chemotherapy. In addition, many women are able to keep their hair, and treatment is administered once every three weeks rather than weekly, making it much easier to manage.
The science behind the drug is highly innovative. Mirvetuximab combines a powerful chemotherapy agent with a specially engineered antibody. These antibodies are designed to recognize a protein called folate receptor alpha, which is found on the surface of certain ovarian cancer cells. Once attached, the cancer cell absorbs the drug, which then releases its chemotherapy payload directly inside the tumour cell, destroying it from within while limiting damage to surrounding healthy cells.
Approximately 30–40% of ovarian cancers that no longer respond to chemotherapy carry this marker, making them suitable for this targeted treatment.
Another patient, 71-year-old Jenny Green from Hertfordshire, participated in the clinical trials that helped demonstrate the drug’s effectiveness. Diagnosed in 2017, Jenny reported experiencing very few side effects during treatment.
“I tolerated it extremely well,” she said. “My scans showed that the cancer nodules were shrinking, and my blood test results improved. That was wonderful news to receive.”
Following positive trial results, the National Institute for Health and Care Excellence (NICE) approved mirvetuximab for patients with ovarian, fallopian tube, and primary peritoneal cancers whose disease no longer responds to chemotherapy and whose tumours express the required biomarker. NHS England has agreed to fund the treatment, meaning eligible patients can now access it through the NHS.
Experts have welcomed the decision, describing it as one of the most significant advances in ovarian cancer treatment in more than two decades. Dr. Rowan Miller, who led the clinical trials at University College London Hospitals, expressed excitement about the drug’s availability, noting that researchers have spent over 20 years searching for more effective treatments for women with hard-to-treat ovarian cancers.
Professor Ruth Plummer, NHS National Clinical Lead for Cancer Drugs, called the therapy the most important breakthrough for this group of patients in over twenty years. Cancer charities, including Ovacome and Target Ovarian Cancer, have also praised the decision, highlighting the urgent need for more effective treatment options for women with platinum-resistant ovarian cancer.
Developed by pharmaceutical company AbbVie, mirvetuximab soravtansine represents a major step forward in personalized cancer treatment. By extending survival while allowing patients to maintain a better quality of life, the drug offers renewed hope for women facing one of the most challenging forms of ovarian cancer.
